BioCentury | Jul 20, 2017
Product R&D

Inducing competition for MSCs

...Status Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) Temcell HS remestemcel-L Ex vivo -cultured adult MSCs Phase III Medipost...
BioCentury | Sep 22, 2014
Clinical News

Pneumostem: Phase I/II start

...Next year, Medipost will begin an open-label, U.S. Phase I/II trial to evaluate intratracheal Pneumostem in...
...Drug designation in the U.S. and Korea, where the product is in Phase II testing. Medipost...
BioCentury | Apr 2, 2012
Finance

Doubling down

...FDA approves FluMist Quadrivalent (MEDI-3250) to prevent seasonal influenza in people ages two to 49 Medipost...
BioCentury | Feb 27, 2012
Clinical News

Cartistem regulatory update

...product is marketed in Korea by partner Dong-A Pharmaceutical Co. Ltd. (KSE:000640, Seoul, South Korea). Medipost...
...also has FDA clearance to conduct a Phase I/IIa trial of Cartistem in the U.S. Medipost...
BioCentury | Feb 23, 2012
Company News

Korea approves Medipost's mesenchymal stem cell therapy

...cord blood. The product is marketed in Korea by partner Dong-A Pharmaceutical Co. Ltd. (KSE:000640). Medipost...
Items per page:
1 - 5 of 5
BioCentury | Jul 20, 2017
Product R&D

Inducing competition for MSCs

...Status Mesoblast Ltd. (ASX:MSB; NASDAQ:MESO) Temcell HS remestemcel-L Ex vivo -cultured adult MSCs Phase III Medipost...
BioCentury | Sep 22, 2014
Clinical News

Pneumostem: Phase I/II start

...Next year, Medipost will begin an open-label, U.S. Phase I/II trial to evaluate intratracheal Pneumostem in...
...Drug designation in the U.S. and Korea, where the product is in Phase II testing. Medipost...
BioCentury | Apr 2, 2012
Finance

Doubling down

...FDA approves FluMist Quadrivalent (MEDI-3250) to prevent seasonal influenza in people ages two to 49 Medipost...
BioCentury | Feb 27, 2012
Clinical News

Cartistem regulatory update

...product is marketed in Korea by partner Dong-A Pharmaceutical Co. Ltd. (KSE:000640, Seoul, South Korea). Medipost...
...also has FDA clearance to conduct a Phase I/IIa trial of Cartistem in the U.S. Medipost...
BioCentury | Feb 23, 2012
Company News

Korea approves Medipost's mesenchymal stem cell therapy

...cord blood. The product is marketed in Korea by partner Dong-A Pharmaceutical Co. Ltd. (KSE:000640). Medipost...
Items per page:
1 - 5 of 5